Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL

11 Feb 2021

Abstract excerpt

MALT1 inhibitors are promising therapeutic agents for B-cell lymphomas that are dependent on constitutive or aberrant signaling pathways. However, a potential limitation for signal transduction-targeted therapies is the occurrence of feedback mechanisms that enable escape from the full impact of such drugs. Here, we used a functional genomics screen in activated B-cell-like (ABC) diffuse large B-cell lymphoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Immune Cell Function and Interaction
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32785655
DOI: 10.1182/blood.2019004713

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCLPMID 32785655Read ↗

Diffuse large B cell lymphoma: molecular targeted therapy.Semantic proximity Read ↗

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaSemantic proximity Read ↗

Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.Semantic proximity Read ↗

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Semantic proximity Read ↗

CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphomaSemantic proximity Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.Semantic proximity Read ↗

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

Transcriptomic profiling in canine B-cell lymphoma supports a synergistic effect of BTK and PI3K inhibitorsSemantic proximity Read ↗

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.Semantic proximity Read ↗

Regulation of B Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell LymphomasSemantic proximity Read ↗

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.